Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

9.475 -0.375 (-3.81%)
Delayed Quote Updated: 3:47 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III ↗
Verastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma,... 
Via MarketBeat
News headline image
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright ↗
Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated... 
Via MarketBeat
News headline image
Verastem (VSTM) Q2 2026 Earnings Call Transcript ↗
Revenue surged on CO-PACK launch as cash runway extends into late 2027. 
Via The Motley Fool
Topics Earnings
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
Via Chartmill
Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects ↗
Via Stocktwits
News headline image
Verastem Q2 Earnings Call Highlights ↗
Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and... 
Via MarketBeat
Topics Earnings
News headline image
Verastem Q1 Earnings Call Highlights ↗
Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade... 
Via MarketBeat
Topics Earnings
News headline image
Verastem (VSTM) Q1 2026 Earnings Transcript ↗
Verastem (VSTM) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗
Verastem (VSTM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗
The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2. 
Via Stocktwits
Topics Earnings
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
A full exit during a volatile stretch raises a sharper question than timing alone. 
Via The Motley Fool
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 
Via Stocktwits
Topics Supply Chain
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Verastem Inc (NASDAQ:VSTM) Reports Q3 2025 Revenue Beat Amid Widened Loss ↗
Verastem's Q3 2025 results show a strong revenue beat from its new cancer drug launch, while its net loss widened. The stock dipped slightly on the mixed earnings news. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish ↗
In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell... 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May ↗
 
Via Benzinga
News headline image
What's Going On With Verastem Oncology Stock On Monday? ↗
Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses. 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer ↗
FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments. 
Via Benzinga
News headline image
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased ↗
The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian... 
Via Stocktwits
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.